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Abstract
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MicroRNAs (miRNAs) are a set of non-coding small RNA molecules in control of gene
expression at posttranscriptional/translational level. They not only play crucial roles in normal
developmental progress, but also are commonly dysregulated in human diseases, including cancer.
MiR-200 is a family of tumor suppressor miRNAs consisting of five members, which are
significantly involved in inhibition of epithelial-to-mesenchymal transition (EMT), repression of
cancer stem cells (CSCs) self-renewal and differentiation, modulation of cell division and
apoptosis, and reversal of chemoresistance. In this article, we summarize the latest findings with
regard to the tumor suppressor signatures of miR-200 and the regulatory mechanisms of miR-200
expression. The collected evidence supports that miR-200 is becoming a new star miRNA in study
of human cancer.
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1. Introduction
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MicroRNAs (miRNAs) are a class of short non-coding RNA molecules with a significant
regulatory capacity on gene expression [1, 2]. Similar to protein-coding genes, the primary
transcripts of miRNA (pri-miRNA) are derived from genomic DNA and synthesized by
RNA polymerase II or III into a hairpin structure [3, 4]. After being further processed by the
RNase III family enzymes, Drosha and DiGeorge syndrome critical region gene 8 (DGCR8),
the excess nucleotides at both the 3′ and 5′ regions of pri-miRNA are cropped off to form
precursor miRNA (pre-miRNA) that is ∼70 nt in length [5-8]. Then, pre-miRNA will be
exported out of the nucleus by the double-stranded RNA binding protein Exportin-5, and
this intermediate product is subsequently cleaved by the RNase III family enzyme, Dicer,
into imperfect mature miRNA:miRNA*duplexes in the cytoplasm [9-13]. The miRNA
strand of approximately 18-22 nucleotides is incorporated into the RNA-induced silencing
complex (RISC), which guides mature miRNA to trigger the target mRNA for subsequent
silencing [14, 15]. Although the extent to which miRNAs regulate the human transcriptome
is still under investigation, more and more evidence supports the fact that miRNA plays a
crucial regulatory role in the control of gene expression.
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To date, a total of 2,578 mature miRNA sequences have been identified in humans in
accordance to the latest release of the miRBase database (http://www.mirbase.org/). The
miRNA-200 family consisting five members (miR-200a, miR-200b, miR-200c, miR-429,
and miR-141), is of particular interest for human health and disease. Based on the
chromosomal locations, the miR-200 family can be divided into two clusters: the
miR-200ba/429 cluster containing miR-200a, miR-200b, and miR-429, which is located on
chromosome 1p36, and the miR-200c/141 cluster, which contains miR-200c and miR-141
and is located on chromosome 12p13. As known, in miRNA biology, seed sequences, in
terms of the complementary sequences to binding sites of miRNA within the 3′ untranslated
regions (UTRs) of the target genes, play a crucial role in regulatory effects of miRNA on
gene expression [16]. Theoretically speaking, the members of a miRNA family contain
highly conservative seed sequences; and miRNAs with the identical seed sequences may
share the same putative target gene profiles. For the miR-200 family, two types of seed
sequences are identified, which only have a nucleotide difference. MiR-200b, miR-200c,
and miR-429 contain AAUACUG, whereas miR-200a and miR-141 possess AACACUG as
their seed sequences. For the convenience of functional analysis, some studies named the
miR-200bc/429 and miR-200a/141 clusters based on the seed sequences and potential
similar target gene profiles [17], which are distinct from miR-200ba/429 and miR-200c/141
that are defined based on the chromosomal locations.
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The first correlative report showing a relationship between the miR-200 family and human
health demonstrated its high olfactory enrichment and neural expression patterns, consistent
with a role in olfactory neurogenesis [18]. Soon afterwards, its involvement in human
disease was confirmed when new studies demonstrated that miR-200 appeared to be
downregulated during tumor progression and acted as a key inhibitor for epithelial-tomesenchymal transition (EMT), tumor cell invasion, and metastasis. These benchmark
results have been summarized in several high quality reviews [19-24]. To be complementary
to these articles, we focus on presentation of the latest findings on studies of miR-200 tumor
suppressive roles in human cancer, which include inhibition of EMT, repression of cancer
stem cell (CSC) self-renewal and differentiation, modulation of cell division and apoptosis,
and involvement in chemoresistance. Moreover, after sorting out many related publications,
we summarize the mechanisms accounting for the regulation of miR-200 expression in
various cancer cells. These results have not yet been collated to date but will be of
importance to understand the tumor suppressor role of miR-200 in human cancer. We hope
that this review article can provide useful insights into translation of the achievements
gained from miRNA research into the future clinical applications.

2. Tumor suppressive signatures of miR-200
NIH-PA Author Manuscript

2.1. Inhibition of epithelial mesenchymal transition (EMT) and tumor metastasis
The involvement of miR-200 in cancer originates from several studies demonstrating a
significant role for miR-200 in EMT, which is an important process in tumor progression as
well as embryonic development. The expression of miR-200 family members was found to
be highly associated with the epithelial phenotype of cancer cells, serving as a class of key
markers for E-cadherin-positive and vimentin-negative cancer cell lines [25-27]. ZEB1 and
ZEB2 are two members of the zinc-finger E-box binding homeobox family, and they have
been defined as the master regulators in EMT [24]. The mechanism by which ZEB1 and
ZEB2 facilitate EMT is that ZEBs can efficiently inhibit the cell-cell adhesion molecule Ecadherin, given that the aberrant expression of E-cadherin is a hallmark of EMT [28]. A
number of studies have documented that, in epithelial cancer cells, highly expressed
miR-200 represses the expression of ZEBs; whereas in mesenchymal cancer cells, impaired
expression of miR-200 leads to induction of ZEBs and subsequent repression of E-cadherin
[25-27]. Following the studies on the ability of miR-200 to regulate the expression of ZEB1
Cancer Lett. Author manuscript; available in PMC 2015 March 28.
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and ZEB2, dozens of others were carried out in various types of human tumors as
summarized in Table 1[29-60]. While expression of the miR-200 family members was
determined to be impaired in various human tumor cells leading to EMT and disease
progression, increased miR-200 family member expression led to a reversal of EMT in
bladder cancer, gastric cancer, nasopharyngeal carcinomas, ovarian cancer, pancreatic
cancer, and prostate cancer [29, 39, 40, 44, 46, 52, 54]. In support of these results, studies by
using clinical patient samples also indicated strong correlations between miR-200
expression and tumor progression in a variety of tumor types[31-33, 35, 37, 39, 41, 42, 45,
47, 48, 50, 53, 54, 56, 58-60]. Furthermore, it has been noted that low level expression of
miR-200 could correlate with poor survival and serve as a prognostic marker for cancer
patients [29, 38, 47, 58-60]. As such, the findings from the studies of miR-200 and EMT
have become the benchmarks for further research on the tumor suppressive signatures of
miR-200.
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EMT is considered the initiating event for cancer metastasis. Two different groups
simultaneously reported that miR-200 was significantly downregulated in metastases and
metastatic-like primary tumors, thereby relieving the repression conferred by the
mesenchymal transcription factor ZEB1 in vivo. Forced expression of miR-200 abrogated
the capacity of tumor cells to undergo invasion and metastasis, underscoring the role for
miR-200 in the regulation of both EMT and subsequent metastases [61, 62]. A similar
conclusion was drawn through studying different human ovarian cancer cell lines with
distinct capabilities to metastasize [63], while miR-200 has also been implicated in the
reversal of the metastatic phenotype of non-small cell lung cancer, as its re-expression has
been shown to downregulate the expression of many prognostic markers for metastasis, such
as alpha thalassemia/mental retardation syndrome X-linked gene (ATRX), deleted in liver
cancer 1 gene (DLC1), hereditary hemochromatosis gene (HFE), and heterogeneous nuclear
ribonucleoprotein A3 gene (HNRNPA3)[43]. Given the mechanistic studies supporting that
the Notch signaling pathway plays a crucial role in the regulation of EMT and thus
metastasis during cancer progression [64], miR-200 was found to decrease expansion of
human metastatic prostate cancer cells by targeting the Notch ligand Jagged1 and the
mastermind-like coactivators Maml2 and Maml3, the key components in the Notch pathway
[65, 66]. Complementary to these results, Yang et al. found that the Notch ligand Jagged2
was also able to inhibit miR-200 family expression at the transcriptional level by induction
of GATA transcription factors, which eventually led to promotion of tumor metastasis in
vivo [67]. These findings support a regulatory loop consisting of miR-200 and the Notch
signaling pathway; the balance of their interaction can potentially decide the stages of tumor
progression (Figure 1A). However, the molecular mechanisms accounting for the tumor
suppressor roles of miR-200 are still largely unknown, although the Notch signaling
pathway sheds light on understanding of its anti-metastatic activity. A recent study reported
the controversial evidence that miR-200 was found to be upregulated in breast cancer 4T1
cells that formed macroscopic metastases in vivo when compared with related cells invading
distant tissues but were unable to colonize. The authors proposed that miR-200 might be
involved in promotion of the last step of the metastatic cascade when establishing
macroscopic metastatic masses at distant sites [68]. Given most current findings supporting
miR-200 as a tumor suppressor, additional evidence is needed to confirm such a hypothesis
in which miR-200 plays an oncogenic role. Together with the myriad of aforementioned
studies from a wide variety of cancers listed in Table 1, these data suggest that the miR-200
family plays a significant role in combating not only EMT, but also tumor cell invasion and
metastases. Thereby, miR-200 has great potential to become a novel class of biomarkers for
tumor prognosis and targets for new drug development against tumor progression.

Cancer Lett. Author manuscript; available in PMC 2015 March 28.

Feng et al.

Page 4

2.2. Repression of cancer stem cell self-renewal and differentiation

NIH-PA Author Manuscript

The most essential feature of stem cells is the capability of self-renewal to produce dozens
of differentiated cell types. The increased evidence shows that miRNAs play a crucial role in
regulating stem cell self-renewal and differentiation. Tumor initiating cells, also called
cancer stem cells (CSCs), have been identified in various types of cancer. The first report
linking miR-200 and stem cell physiology came in 2009 from a study in which all five
members of the miR-200 family were shown to be downregulated in human breast CSCs as
well as in normal human and murine mammary stem/progenitor cells [69]. By targeting B
lymphoma Mo-MLV insertion region 1 homolog (BMI1), a known regulator for stem cell
self-renewal, miR-200c was shown to strongly suppress the ability of normal mammary
stem cells from forming mammary ducts and tumor formation driven by human breast CSC
in vivo [69]. Not only can miR-200c suppress tumor formation driven by breast CSCs, but
miR-200b can downregulate CSC growth through targeting the Polycomb family embryonic
stem (ES) cell pluripotency maintenance factor Suz12 [70]. Moreover, Lim et al. reported
that the immortalized human mammary epithelial cells convert from a non-stem to a stem
cell-like phenotype accompanied with a loss of miR-200 expression. Restoration of miR-200
expression decreased stem-like properties while promoting a transition to an epithelial
phenotype [71]. Thus, it is apparent that miR-200 family members play important roles in
multiple events related to CSCs.
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Many of the molecular factors needed to maintain pluripotency of stem cells have been
found to regulate the expression of the miR-200 family of miRNAs, such as c-Myc, octamerbinding transcription factor 4 (Oct4), and sex determining region Y-box 2 (Sox2). Lin et al.
reported that the expression of the miR-200 family was regulated by c-Myc in ES cells. The
transcriptional induction of these miRNAs by c-Myc significantly attenuated the
downregulation of pluripotency markers, which indicates that in ES cells, c-Myc acts, at
least in part, through the miR-200 family to attenuate differentiation [72]. In addition, Wang
et al. found that Oct4 and Sox2 induced the transcriptional activation of the miR-200 family,
which promoted the mesenchymal-to-epithelial transition (MET) and the generation of
induced pluripotent stem cells (iPSCs) by targeting ZEB2 [73], thus leading to somatic cell
reprogramming. However, in proliferating vMH (ventral midbrain/hindbrain) neural
progenitors, miR-200 was required to promote cell-cycle exit and neuronal differentiation
through targeting the expression of Sox2 and the cell cycle regulator E2F3 [74].
Samavarchi-Tehrani et al. also found that during the initiation phase of reprogramming, the
bone morphogenetic protein (BMP) signaling could induce the expression of miR-200 and
miR-205, forming a multistep mechanism that incorporates a BMP-miRNA-MET axis to
promote somatic cell reprogramming [75]. Thus, as illustrated in Figure 1B, the miR-200
family has been demonstrated to bear integral importance in the process of self-renewal and
differentiation of CSCs.
2.3. Modulatory role of miR-200 in cell division and apoptosis
Cell division is a vital process used by a single fertilized egg to develop into a mature
organism, as well as to renew cells, tissues, and thus organs. The control of the cell cycle by
miRNA is well established, and ectopic expression of certain miRNAs may contribute to
tumor development by perturbing important cell cycle regulators. Uhlmann et al. were the
first to describe a role for miR-200 in regulating cell cycle progression in breast cancer [17].
They found that overexpression of miR-200a/141 resulted in G1 arrest, which may be due to
increased expression of cyclin dependent kinase inhibitor 1B (p27/Kip1) and decreased
expression of cyclin dependent kinase 6 (CDK6). In contrast, elevating the expression
miR-200bc/429 cluster caused a reduction of p27/Kip1 expression and upregulation of
inhibitory phosphorylation of cell division cycle 25C gene (CDC25C), thereby decreasing
the G1 population and increasing the G2/M population [17]. It is noticed that, in this study,
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the miR-200bc/429 and miR-200a/141 clusters are defined by using the different seed
sequences and target gene pools, which account for, at least in part, their distinct functions
in regulation of cell cycle. Xia et al. found that, in HeLa cells, miR-200b directly
downregulated Rho family GTPase 3 (RND3), thereby promoting expression of the
downstream cell cycle regulatory factor cyclin D1 (CCND1) that controls S-phase entry
[76]. More recently, Yao et al. demonstrated that miR-200b was a critical regulator of the
zinc finger transcription factor GATA-4, which regulates the expression of CCND1 at the
transcriptional level. Their results supported that miR-200b could regulate tumor cell growth
and differentiation by targeting GATA-4 to downregulate the expression of CCND1 [77].
Thus, these findings support that miR-200 can exert control over the cell cycle at many
levels through the modulation of several different factors.

NIH-PA Author Manuscript

In addition to playing a role in the regulation of cell cycle, the miR-200 family has been
shown to modulate apoptosis. Schickel et al. found that altering levels of miR-200c changed
the sensitivity of cells to death receptor CD95-mediated apoptosis [78]. In addition, they
identified the apoptosis inhibitor, Fas-associated phosphatase-1 (FAP-1), as a target of
miR-200c, which was demonstrated to be responsible for the reduced sensitivity of CD95mediated apoptosis in cells with inhibited miR-200. It was also reported that reactive oxygen
species (ROS) could induce miR-200 family expression with subsequent downmodulation of
ZEB1, which was likely to play a key role in ROS-induced apoptosis and senescence [79].
Figure 1C illustrates the involvement of miR-200 in regulation of cell division and
apoptosis.
2.4 Reversal of chemoresistance
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Although the mechanisms have not yet been completely understood, the chemoresistance to
a few drugs, such as gemcitabine, paclitaxel, cisplatin, doxorubicin, docetaxel, EGFR
inhibitors, and vincristine, has been reported to be associated with the downregulation of
miR-200 [80-88]. Interestingly, some of these studies also reported that the restoration of
miR-200 could effectively reverse the chemoresistance to certain drugs [82, 87, 88]. Meng
et al. first reported that inhibition of miR-200b expression could increase the sensitivity of
cholangiocarcinoma cells to the nucleoside analog gemcitabine [80]. Ali et al. reported that
the curcumin analogue CDF (a novel turmeric spice analogue) was able to cause reactivation
of miR-200b/c, which in turn resulted in the reversal of the EMT phenotype and thus
sensitized pancreatic cancer cells to gemcitabine [81]. Cochrane et al. found that restoration
of miR-200c could enhance the sensitivity of the antimicrotubule agent paclitaxel in
resistant cancer cells through targeting TUBB3, which encodes class III β tubulin [82]. In
breast cancer MCF7 cells, the miR-200 family was specifically down-regulated in those
cells resistant to two therapeutic agents commonly used in the treatment of breast cancer,
doxorubicin or cisplatin [83, 84]. By miRNA microarray, Wang et al. found that miR-200b
was identified as the most downregulated miRNA in docetaxel-resistant human lung
adenocarcinoma (SPC-A1/DTX) cells compared with the parental (SPC-A1) cells [85].
When examining the miRNA expression from lung adenocarcinoma patients treated with
docetaxel-based chemotherapy, aberrant expression of miR-200b was correlated with
decreased sensitivity to the antimitotic agent docetaxel [86]. Additionally, miR-200
expression correlated with sensitivity to epidermal growth factor receptor (EGFR) blocking
agents in bladder cancer, and restoration of miR-200 increased the sensitivity in
mesenchymal-like cell lines [87]. Recently, Zhu et al. reported that the miR-200bc/429
cluster was impaired in vincristine-resistant gastric cancer cells and cisplatin-resistant lung
cancer cells. However, the restoration of the miR-200bc/429 cluster could sensitize the
tumors cells to chemotherapy. The mechanistic studies suggested that this effect resulted
from, at least partially, recurred apoptosis led by the suppressive effect of miR-200 on two
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anti-apoptotic factors, B-cell lymphoma 2 gene (BCL-2) and X-linked inhibitor of apoptosis
protein gene (XIAP)[88].
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In summary, aside from the well-documented inhibitory effect on EMT, many novel tumor
suppressive signatures of miR-200 have been identified in various human cancer cells, such
as inhibition of CSC self-renewal and differentiation, modulation of cell division and
apoptosis, and reversal of chemoresistance. Figure 1 illustrates the tumor suppressor roles of
miR-200 that have been discussed in this article. These findings will support that miR-200
not only is a valuable biomarker for tumorigenesis and progression, but can also become a
potential target for new drug development.

3. Regulation of miR-200 expression
Given that miRNA is a class of non-coding small RNA molecules, the transcription factor
involved regulation and epigenetic modulation are two major mechanisms that contr o l
miRNA expression. Due to the increased interest in miR-200 as well as its tumor suppressor
role in a variety of human tumors, better understanding of miR-200 regulatory mechanisms
can provide insights into the future translation of miR-200's tumor suppressive signatures
into development of novel strategies for treating human cancer. Here, we will summarize the
latest research results on studies of miR-200 expression regulation.
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3.1 Transcription factor involved regulation
Regulatory mechanisms for miR-200's expression have been studied in dozens of cell types,
during which several essential transcription factors have been determined to be involved. In
addition to the master inducers of EMT, ZEB1 and ZEB2 are known as the transcription
factors containing zinc-finger domains [24]. Within the putative promoter region of
miR-200c/141 and in spacers between the miR-200c and miR-141 stem loops, there are two
highly conserved Z-box and four E-box transcription factor binding motifs to which ZEB1
can bind for suppression of this family's polycistronic transcription [89]. Similarly, ZEB1
and ZEB2 can also repress miR-200ba/429 polycistronic transcription by binding to their
regulatory E-boxes [90]. Interestingly, ZEB1 and ZEB2 were also demonstrated as targets of
miR-200 so that they form a mutually inhibitory feedforward loop as shown in Figure 1A
[24-27]. Additionally, two other related transcription factors known to be associated with
EMT, Snail and Slug, were shown to be able to negatively regulate transcription of
miR-200, providing additional evidence in support of the involvement of miR-200 in EMT
[91, 92].
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Members of various other transcription factor families have also been shown to be involved
in the regulated expression of miR-200. Mizuguchi et al. reported that regulation of miR-200
transcription by ZEB1 could be modulated via the involvement of the transcription factors
P300 and PCAF [93]. They found that the activation of miR-200c/141 transcription occurred
when P300 and PCAF physically interacted to form a transcriptional complex involving
ZEB1, while disruption of the P300-PCAF interaction significantly suppressed the
transcriptional activity [93]. A recent study report that the proto-oncogene c-Myb was able
to upregulate all miR-200 miRNA family members through the transcriptional regulation,
whereas this inductive effect could be completely attenuated by ZEB1 at the onset of EMT
[94]. A previous study also reported that miR-200b, miR-200c, and miR-429 target c-Myb
and repress its expression [95]. Therefore, a reciprocal feedback loop may involve the
mutual regulation between miR-200 and c-Myb. Another factor recently demonstrated to
directly modulate the expression of miR-200a and miR-141 is the gene named proline,
glutamic acid and leucine rich protein 1 (PELP1), a nuclear receptor that can be selfupregulated during the metastatic progression of breast cancer cells [96]. PELP1 is found to
form a complex with histone deacetylating ezymes (HDAC2) that binds to the miR-200's
Cancer Lett. Author manuscript; available in PMC 2015 March 28.

Feng et al.

Page 7

NIH-PA Author Manuscript

promoters, thereby downregulating their expression [96]. Kim et al. reported that inhibitory
effect of P53 on EMT involves the transactivation of miR-200; miR-200 repressing ZEBs is
responsible for P53 regulated EMT [97]. In addition, P63 and P73, the members of the P53
transcription factor family, can also directly regulate transcription of miR-200 through
binding with the p53/p63/p73 binding sites within the promoter regions of both miR-200
clusters [98]. Ahn et al. recently reported that Smad3 can transcriptionally induce miR-200
in a transforming growth factor β (TGF-β) independent manner, accounting for its
suppressive effect on EMT in gastric cancer cells [99].
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As discussed earlier, the transcription factors c-Myc, Oct4, and Sox2, which are largely
essential for maintenance of pluripotency in stem cells, also play critical roles in regulating
miR-200 family expression. In ES cells, c-Myc can upregulate miR-200b that leads to
attenuation of ES differentiation [72], whereas in the endometrial cancer cells treated with
tamoxifen, miR-200 repressed by elevated c-Myc and associated with the onset of EMT
[100]. During iPSC reprogramming from fibroblasts, exogenous Oct4 and Sox2 can bind the
promoter regions of the miR-200ba/429 and miR-200c/141 clusters, respectively, to activate
their transcription [73], suggesting that miR-200 is involved in reprogramming and stem cell
self-renewal, whereas Sox2 and E2F3 can activate the transcription of miR-200c/141 cluster
in vivo [74]. In addition, the TGF-β pathway ligand, bone morphogenetic protein (BMP7),
was shown to synergize with the Yamanaka factors (Oct4, Klf, c-Myc, and Sox2) to induce
miR-200 expression during the initial reprogramming phase of iPSC generation involving
MET [75]. As such, many different molecular factors have been documented to control the
regulated expression of miR-200, which in turn shows variable downstream effects on
human diseases.
3.2 Epigenetic modification
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Aside from the regulated expression conferred by the aforementioned transcription factors,
epigenetic modification in the form of DNA methylation has been determined to control
miR-200 family expression in both normal and cancer cells [101]. Substantial cytosine
methylation, usually in CpG islands located within the gene's promoter region, has been
documented as an epigenetic marker of gene repression. Studies have reported that the
regulatory regions of both miR-200 clusters contain CpG-rich sequences. Li et al. reported
the epigenetic regulation of miR-200 expression when they showed that miR-200a and
miR-200b were hypomethylated and overexpressed in pancreatic cancer cells [52]. Vrba et
al. found that in miR-200c/141-negative normal and tumor cells, its CpG island was heavily
methylated, whereas in miR-200c/141-expressing cells, the CpG island was unmethylated
[101], indicating a role for DNA methylation in miR-200c/141 regulation in both normal
and tumor cells. In addition, mouse cells showed a similar correlation between DNA
methylation and miR-200c expression. Wiklund et al. found that in muscle invasive bladder
tumors and undifferentiated bladder cell lines, both miR-200 clusters were silenced
concomitant with DNA hypermethylation, while in oral squamous cell carcinoma, miR-200
was epigenetically activated [29, 45]. More recently, the focal adhesion protein Kindlin 2
was found to form a complex with DNA (cytosine-5-)-methyltransferase 3 alpha
(DNMT3A) in the breast cancer cell nucleus to induce CpG island hypermethylation of the
miR-200 promoter in order to downregulate the expression of the miR-200 family [102]. It
is of note that the aforementioned cases in which DNA methylation was used to
downregulate miR-200 expression seemed to correlate with increased tumor formation and/
or cell invasion.
In addition to DNA methylation, histone modification is another major class of epigenetic
modulation used to regulate expression of the miR-200 family. Tellez et al. reported that a 4week exposure of immortalized human bronchial epithelial cells to tobacco carcinogens
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could induce EMT, most likely due to the silencing of miR-200b, miR-200c and
miR-205,which occurred due to methylation initiated at histone H3 (H3K27me3) and later
by increasing DNA methylation [103]. Recently, Lim et al. found that in the stem-like
phenotype of immortalized human mammary epithelial cells, the miR-200ba/429 cluster was
silenced primarily through histone modifications, whereas the miR-200c/141 cluster was
repressed via DNA methylation [71]. More recently and interestingly, Zhang et al. found
that the H19 long non-coding RNA (lncRNA) is associated with the hnRNPU/PCAF/RNA
Pol II complex, which is able to activate the miR-200 family via histone acetylation [104].
Treatment of an endocrine-resistant breast cancer cell line with both a demethylating agent
as well as a deacetylating agent resulted in an increase in expression of both miR-200b and
miR-200c, leading to a repression of ZEB1 and showing more epithelial-like characteristics
[105]. Thus, it is clear that epigenetic modulation, including DNA methylation as well as
histone methylation and acetylation, plays an essential role in the regulated expression of the
miR-200 family.
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The molecular mechanisms and related factors are mapped on Figure 2, illustrating the
transcriptional regulation of miR-200 expression. In addition to the transcription factor
involved regulation and epigenetic modification, other mechanisms/factors have also been
studied. For example, Iliopoulos et al. reported that miR-200 was differentially regulated by
two of the serine/threonine kinase Akt isoforms in breast cancer cells [106]. As they found
that miR-200 family expression was decreased in either cells bearing Akt2 or cells of Akt 1
knockdown, but unaltered in cells of Akt2 knockdown or both Akt1 and Akt2 knockdown, it
was inferred that miR-200 expression may be dependent on the balance between Akt1 and
Akt2[106]. However, in prostate cancer, silencing of Akt2 is able to inversely induce the
expression of miR-200 [107]. These findings suggest that Akt is involved in the regulation
of miR-200 expression, although the mechanism of action has not been uncovered.

4. Conclusion and Perspective
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The inhibitory effect of miR-200 on EMT by targeting ZEBs is the benchmark achievement
to understand the tumor suppressor roles of miR-200 in human cancer. As discussed earlier,
the promoter regions of both miR-200 clusters have binding sites for ZEB1 and ZEB2
transcription factors. Interestingly, both ZEBs can be targeted by miR-200, reciprocally,
hinting at a possible unknown mechanism by which a feedback inhibition loop can be
broken and cells can be switched between an epithelial and mesenchymal phenotype. Given
the miR-200 family functioning as a potential suppressor of EMT to prevent malignant
tumor progression, future work may improve our understanding of miR-200's role in cancer
progression by identification and functional characterization of additional downstream
targets of miR-200 that might be involved in multiple cellular events. Moreover, the newly
identified tumor suppressor roles of miR-200, such as inhibition of CSC self-renewal and
differentiation, modulation of cell division and apoptosis, and reversal of chemoresistance,
are of significance to support that miR-200 is a new star miRNA in cancer research. In
addition to the updats of new knowledge with regard to the tumor suppressive signatures of
miR-200, we sort out the latest findings and summarize the mechanisms involved in the
regulation of miR-200 expression. Given the non-coding nature of miRNA, transcription
regulation involving multiple transcription factors and epigenetic modulation including
DNA methylation and histone modification are major forms accounting for the regulatory
basis of miR-200 expression. The understanding of these regulatory mechanisms can not
only deepen our understanding of miR-200 anticancer activity, but also aid us in
development of novel drugs to target these small molecules.
To date, there are 236 publications collected in PUBMED with regard to miR-200 and
cancer; however, more than 75% of these publications are published over the past three
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years (from September 2010 to August 2013), which indicates the growing interest in the
study of miR-200. Due to the tumor suppressive signature of miR-200, a proposal for
restoring miR-200 expression may be taken into consideration as a novel therapeutic to treat
human cancer, although the development of such a strategy still depends on a better
understanding of the mechanistic basis of miR-200 anticancer activity. In the near future,
studying the relationship between miR-200 and CSCs, coupled with improvements of drug
delivery systems, may also become a promising area to discover novel therapeutics for
treating human cancer efficaciously.
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Figure 1.

Tumor suppressive signatures of miR-200. (A) MiR-200 inhibits EMT by interacting with
ZEB1/2 and the Notch pathway. (B) MiR-200 represses self-renewal and differentiation in
CSCs. (C) MiR-200 is involved in the regulation of cell division and apoptosis.
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Figure 2.

Regulation of miR-200 expression involving multiple transcription factors (TFs) and
epigenetic modification. TSS represents transcription starting site. * TFs determined in
mouse models.
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Table 1

Dysregulation of miR-200 in various human cancers
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Members of miR-200 family

Cancer types

References

miR-200a, 200b, 200c, 141

Bladder cancer

[29]

miR-200a, 200b, 200c, 141, 429

Breast cancer

[30-32]

miR-200a, 200b, 200c

Colorectal cancer

[33; 34; 58]

miR-200a, 200c

Cutaneous melanoma

[35]

miR-200a, 200b, 200c, 141, 429

Endometrial cancer

[36; 37]

miR-200a, 200b, 200c, 141

Gastric cancer

[38-41]

miR- 200c

Hepatocellular tumor

[42]

miR-200a, 200b, 200c, 141, 429

Lung cancer

[43; 59]

miR-200a

Nasopharyngeal carcinoma

[44]

miR-200a, 200b, 200c, 141, 429

Oral squamous cell carcinoma

[45]

miR-200a, 200b, 200c, 141, 429

Ovarian cancer

[46-51]

miR-200a, 200b

Pancreatic cancer

[52; 60]

miR-200b, 200c, 141, 429

Pleural mesothelioma

[53]

miR-200a

Prostate cancer

[54]

miR-200a, 200b, 200c, 141

Renal cell carcinoma

[55]

miR-200a, 200c, 141, 429

Spindle cell carcinoma of the head and neck

[56]

miR-200a, 200b, 200c, 141

Thyroid carcinoma

[57]
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